Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.

For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM200-300 per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.

For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM200-300 per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

There are 23 potential vaccines developed and 3 candidates already passed the clinical trial and go for final stage of testing.
1. Moderna vaccine enter the final stage of human trials for its COVID-19 vaccine on July 27.
2. Oxford-AstraZeneca Covid-19 vaccine show good immune responses without side effect.
3. Chinese-made vaccine from Sinovac Biotech at final stage of testing in Brazil.

PATHOLOGY SERVICES - LABLINK (M) SDN BHD provide laboratory/pathology services to the KPJ Group. It manages the pathology laboratories in KPJ’s network of hospitals. Lablink also conducts clinical tests for more than 100 non-KPJ institutions (including hospitals under the Ministry of Health and University Hospitals) as wellas general practitioners’ clinics across Malaysia. Lablink is the first lab in Malaysia to be certified with Bio-Safety Level 3 (BSL3) facilities which allows testing of highly infectious diseases (according to World Health Organization (WHO) standards). In Mar 2020, Lablink was one of the private laboratories listed by the Ministry of Health (MOH) to perform COVID-19 rRT-PCR (i.e. real-time reverse transcription polymerase chain reaction) by testing specimens received from hospitals: both from walk-in members of the public as well as hospital inpatients. Lablink recorded revenue of RM102.2 million in 2019.
The KPJ group of Hospitals classified Covid 19 rRT-PCR test according to urgent (result within 24 hours) and routine (beyond 24 hours). The COVID-19 testing capacity has been ramped up and Lablink has been able to test and report about 1,500-3,000 samples in a day in May 2020. The total number of samples, as at the end of May 2020 was in excess of 70,000; of which the KPJ-Group of Hospitals Nationwide contributed to almost 75% of the tests while the balance was from non-KPJ hospitals and the Ministry of Health.

PHARMASERV ALLIANCES SDN BHD (PASB) is KPJ’s centralized wholesaler and distributor of pharmaceutical, medical disposables and other hospital related products. Its clients are the KPJ network of hospitals and companies, as well as external clients within the government sector and other healthcare sector players. PASB is able to achieve profitable growth and retain a competitive edge by transferring cost savings to customers. In 2019, its revenue increased to RM451.1 million.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.

For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM200-300 per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

There are 23 potential vaccines developed and 3 candidates already passed the clinical trial and go for final stage of testing.
1. Moderna vaccine enter the final stage of human trials for its COVID-19 vaccine on July 27.
2. Oxford-AstraZeneca Covid-19 vaccine show good immune responses without side effect.
3. Chinese-made vaccine from Sinovac Biotech at final stage of testing in Brazil.

PATHOLOGY SERVICES - LABLINK (M) SDN BHD provide laboratory/pathology services to the KPJ Group. It manages the pathology laboratories in KPJ’s network of hospitals. Lablink also conducts clinical tests for more than 100 non-KPJ institutions (including hospitals under the Ministry of Health and University Hospitals) as wellas general practitioners’ clinics across Malaysia. Lablink is the first lab in Malaysia to be certified with Bio-Safety Level 3 (BSL3) facilities which allows testing of highly infectious diseases (according to World Health Organization (WHO) standards). In Mar 2020, Lablink was one of the private laboratories listed by the Ministry of Health (MOH) to perform COVID-19 rRT-PCR (i.e. real-time reverse transcription polymerase chain reaction) by testing specimens received from hospitals: both from walk-in members of the public as well as hospital inpatients. Lablink recorded revenue of RM102.2 million in 2019.
The KPJ group of Hospitals classified Covid 19 rRT-PCR test according to urgent (result within 24 hours) and routine (beyond 24 hours). The COVID-19 testing capacity has been ramped up and Lablink has been able to test and report about 1,500-3,000 samples in a day in May 2020. The total number of samples, as at the end of May 2020 was in excess of 70,000; of which the KPJ-Group of Hospitals Nationwide contributed to almost 75% of the tests while the balance was from non-KPJ hospitals and the Ministry of Health.

PHARMASERV ALLIANCES SDN BHD (PASB) is KPJ’s centralized wholesaler and distributor of pharmaceutical, medical disposables and other hospital related products. Its clients are the KPJ network of hospitals and companies, as well as external clients within the government sector and other healthcare sector players. PASB is able to achieve profitable growth and retain a competitive edge by transferring cost savings to customers. In 2019, its revenue increased to RM451.1 million.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.

For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM200-300 per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

There are 23 potential vaccines developed and 3 candidates already passed the clinical trial and go for final stage of testing.
1. Moderna vaccine enter the final stage of human trials for its COVID-19 vaccine on July 27.
2. Oxford-AstraZeneca Covid-19 vaccine show good immune responses without side effect.
3. Chinese-made vaccine from Sinovac Biotech at final stage of testing in Brazil.

PATHOLOGY SERVICES - LABLINK (M) SDN BHD provide laboratory/pathology services to the KPJ Group. It manages the pathology laboratories in KPJ’s network of hospitals. Lablink also conducts clinical tests for more than 100 non-KPJ institutions (including hospitals under the Ministry of Health and University Hospitals) as wellas general practitioners’ clinics across Malaysia. Lablink is the first lab in Malaysia to be certified with Bio-Safety Level 3 (BSL3) facilities which allows testing of highly infectious diseases (according to World Health Organization (WHO) standards). In Mar 2020, Lablink was one of the private laboratories listed by the Ministry of Health (MOH) to perform COVID-19 rRT-PCR (i.e. real-time reverse transcription polymerase chain reaction) by testing specimens received from hospitals: both from walk-in members of the public as well as hospital inpatients. Lablink recorded revenue of RM102.2 million in 2019.
The KPJ group of Hospitals classified Covid 19 rRT-PCR test according to urgent (result within 24 hours) and routine (beyond 24 hours). The COVID-19 testing capacity has been ramped up and Lablink has been able to test and report about 1,500-3,000 samples in a day in May 2020. The total number of samples, as at the end of May 2020 was in excess of 70,000; of which the KPJ-Group of Hospitals Nationwide contributed to almost 75% of the tests while the balance was from non-KPJ hospitals and the Ministry of Health.

PHARMASERV ALLIANCES SDN BHD (PASB) is KPJ’s centralized wholesaler and distributor of pharmaceutical, medical disposables and other hospital related products. Its clients are the KPJ network of hospitals and companies, as well as external clients within the government sector and other healthcare sector players. PASB is able to achieve profitable growth and retain a competitive edge by transferring cost savings to customers. In 2019, its revenue increased to RM451.1 million.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.

For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM200-300 per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.

For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM200-300 per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.

For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM200-300 per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.

For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM200-300 per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.

For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM200-300 per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.

For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM200-300 per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.

For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM200-300 per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.

For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM200-300 per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

CGS CIMB expected total occupancy rates of about 52% for the financial year ending Dec 31,2020 (FY20), which is a slight dip from FY19’s occupancy rate of 67% https://www.thestar.com.my/business/business-news/2020/08/10/kpj-expected-to-see-recovery-in-occupancy.

Many broker expert try to predict how economy growth and now they are tried to predict how medical sector performance in the future although they have totally zero knowledge on health science.

End game
Moderna prices Covid-19 vaccine at US$32-US$37 per dose for smaller-volume deals. https://www.theedgemarkets.com/article/moderna-prices-covid19-vaccine-us32us37-dose-smallervolume-deals

KPJ Indonesian hospitals recording revenue RM56.9Mil and Loss before tax 9.8Mil in 2019. Private healthcare mostly served T20 and M40 population thus higher living standard a country is more population willing to choose better healthcare system like Singapore.

IHH- 15 hospitals in Malaysia total 2,372 beds (PE40)

KPJ- 28 hospitals in Malaysia total 3,200 beds (PE16)

TMC Life- 1 hospital in Malaysia total 600 beds (PE-Neg)

Every com hv it strength and opportunity.
IHH more expansion globally.
KPJ truly dominated Malaysia market in every states.
TMCLife is well-known healthcare sector in Singapore.

Moderna Inc is planning to price its coronavirus vaccine at US$50 to $60 per course, at least $11 more than another vaccine from Pfizer Inc and BioNTech.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.

For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM1k-2k per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

There are 23 potential vaccines developed and 3 candidates already passed the clinical trial and go for final stage of testing.
1. Moderna vaccine enter the final stage of human trials for its COVID-19 vaccine on July 27.
2. Oxford-AstraZeneca Covid-19 vaccine show good immune responses without side effect.
3. Chinese-made vaccine from Sinovac Biotech at final stage of testing in Brazil.

PATHOLOGY SERVICES - LABLINK (M) SDN BHD provide laboratory/pathology services to the KPJ Group. It manages the pathology laboratories in KPJ’s network of hospitals. Lablink also conducts clinical tests for more than 100 non-KPJ institutions (including hospitals under the Ministry of Health and University Hospitals) as wellas general practitioners’ clinics across Malaysia. Lablink is the first lab in Malaysia to be certified with Bio-Safety Level 3 (BSL3) facilities which allows testing of highly infectious diseases (according to World Health Organization (WHO) standards). In Mar 2020, Lablink was one of the private laboratories listed by the Ministry of Health (MOH) to perform COVID-19 rRT-PCR (i.e. real-time reverse transcription polymerase chain reaction) by testing specimens received from hospitals: both from walk-in members of the public as well as hospital inpatients. Lablink recorded revenue of RM102.2 million in 2019.
The KPJ group of Hospitals classified Covid 19 rRT-PCR test according to urgent (result within 24 hours) and routine (beyond 24 hours). The COVID-19 testing capacity has been ramped up and Lablink has been able to test and report about 1,500-3,000 samples in a day in May 2020. The total number of samples, as at the end of May 2020 was in excess of 70,000; of which the KPJ-Group of Hospitals Nationwide contributed to almost 75% of the tests while the balance was from non-KPJ hospitals and the Ministry of Health.

PHARMASERV ALLIANCES SDN BHD (PASB) is KPJ’s centralized wholesaler and distributor of pharmaceutical, medical disposables and other hospital related products. Its clients are the KPJ network of hospitals and companies, as well as external clients within the government sector and other healthcare sector players. PASB is able to achieve profitable growth and retain a competitive edge by transferring cost savings to customers. In 2019, its revenue increased to RM451.1 million.

Regardless of Covid 19 outbreak, KPJ remain resilient of its business model. The group switches over to ramp up testing services and can generate augur profit to offset any downturn during outbreak.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.

For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM1k-2k per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

There are 23 potential vaccines developed and 3 candidates already passed the clinical trial and go for final stage of testing.
1. Moderna vaccine enter the final stage of human trials for its COVID-19 vaccine on July 27.
2. Oxford-AstraZeneca Covid-19 vaccine show good immune responses without side effect.
3. Chinese-made vaccine from Sinovac Biotech at final stage of testing in Brazil.

PATHOLOGY SERVICES - LABLINK (M) SDN BHD provide laboratory/pathology services to the KPJ Group. It manages the pathology laboratories in KPJ’s network of hospitals. Lablink also conducts clinical tests for more than 100 non-KPJ institutions (including hospitals under the Ministry of Health and University Hospitals) as wellas general practitioners’ clinics across Malaysia. Lablink is the first lab in Malaysia to be certified with Bio-Safety Level 3 (BSL3) facilities which allows testing of highly infectious diseases (according to World Health Organization (WHO) standards). In Mar 2020, Lablink was one of the private laboratories listed by the Ministry of Health (MOH) to perform COVID-19 rRT-PCR (i.e. real-time reverse transcription polymerase chain reaction) by testing specimens received from hospitals: both from walk-in members of the public as well as hospital inpatients. Lablink recorded revenue of RM102.2 million in 2019.
The KPJ group of Hospitals classified Covid 19 rRT-PCR test according to urgent (result within 24 hours) and routine (beyond 24 hours). The COVID-19 testing capacity has been ramped up and Lablink has been able to test and report about 1,500-3,000 samples in a day in May 2020. The total number of samples, as at the end of May 2020 was in excess of 70,000; of which the KPJ-Group of Hospitals Nationwide contributed to almost 75% of the tests while the balance was from non-KPJ hospitals and the Ministry of Health.

PHARMASERV ALLIANCES SDN BHD (PASB) is KPJ’s centralized wholesaler and distributor of pharmaceutical, medical disposables and other hospital related products. Its clients are the KPJ network of hospitals and companies, as well as external clients within the government sector and other healthcare sector players. PASB is able to achieve profitable growth and retain a competitive edge by transferring cost savings to customers. In 2019, its revenue increased to RM451.1 million.

Regardless of Covid 19 outbreak, KPJ remain resilient of its business model. The group switches over to ramp up testing services and can generate augur profit to offset any downturn during outbreak.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.

For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM1k-2k per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

There are 23 potential vaccines developed and 3 candidates already passed the clinical trial and go for final stage of testing.
1. Moderna vaccine enter the final stage of human trials for its COVID-19 vaccine on July 27.
2. Oxford-AstraZeneca Covid-19 vaccine show good immune responses without side effect.
3. Chinese-made vaccine from Sinovac Biotech at final stage of testing in Brazil.

PATHOLOGY SERVICES - LABLINK (M) SDN BHD provide laboratory/pathology services to the KPJ Group. It manages the pathology laboratories in KPJ’s network of hospitals. Lablink also conducts clinical tests for more than 100 non-KPJ institutions (including hospitals under the Ministry of Health and University Hospitals) as wellas general practitioners’ clinics across Malaysia. Lablink is the first lab in Malaysia to be certified with Bio-Safety Level 3 (BSL3) facilities which allows testing of highly infectious diseases (according to World Health Organization (WHO) standards). In Mar 2020, Lablink was one of the private laboratories listed by the Ministry of Health (MOH) to perform COVID-19 rRT-PCR (i.e. real-time reverse transcription polymerase chain reaction) by testing specimens received from hospitals: both from walk-in members of the public as well as hospital inpatients. Lablink recorded revenue of RM102.2 million in 2019.
The KPJ group of Hospitals classified Covid 19 rRT-PCR test according to urgent (result within 24 hours) and routine (beyond 24 hours). The COVID-19 testing capacity has been ramped up and Lablink has been able to test and report about 1,500-3,000 samples in a day in May 2020. The total number of samples, as at the end of May 2020 was in excess of 70,000; of which the KPJ-Group of Hospitals Nationwide contributed to almost 75% of the tests while the balance was from non-KPJ hospitals and the Ministry of Health.

PHARMASERV ALLIANCES SDN BHD (PASB) is KPJ’s centralized wholesaler and distributor of pharmaceutical, medical disposables and other hospital related products. Its clients are the KPJ network of hospitals and companies, as well as external clients within the government sector and other healthcare sector players. PASB is able to achieve profitable growth and retain a competitive edge by transferring cost savings to customers. In 2019, its revenue increased to RM451.1 million.

Regardless of Covid 19 outbreak, KPJ remain resilient of its business model. The group switches over to ramp up testing services and can generate augur profit to offset any downturn during outbreak.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.

For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM1k-2k per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

There are 23 potential vaccines developed and 3 candidates already passed the clinical trial and go for final stage of testing.
1. Moderna vaccine enter the final stage of human trials for its COVID-19 vaccine on July 27.
2. Oxford-AstraZeneca Covid-19 vaccine show good immune responses without side effect.
3. Chinese-made vaccine from Sinovac Biotech at final stage of testing in Brazil.

PATHOLOGY SERVICES - LABLINK (M) SDN BHD provide laboratory/pathology services to the KPJ Group. It manages the pathology laboratories in KPJ’s network of hospitals. Lablink also conducts clinical tests for more than 100 non-KPJ institutions (including hospitals under the Ministry of Health and University Hospitals) as wellas general practitioners’ clinics across Malaysia. Lablink is the first lab in Malaysia to be certified with Bio-Safety Level 3 (BSL3) facilities which allows testing of highly infectious diseases (according to World Health Organization (WHO) standards). In Mar 2020, Lablink was one of the private laboratories listed by the Ministry of Health (MOH) to perform COVID-19 rRT-PCR (i.e. real-time reverse transcription polymerase chain reaction) by testing specimens received from hospitals: both from walk-in members of the public as well as hospital inpatients. Lablink recorded revenue of RM102.2 million in 2019.
The KPJ group of Hospitals classified Covid 19 rRT-PCR test according to urgent (result within 24 hours) and routine (beyond 24 hours). The COVID-19 testing capacity has been ramped up and Lablink has been able to test and report about 1,500-3,000 samples in a day in May 2020. The total number of samples, as at the end of May 2020 was in excess of 70,000; of which the KPJ-Group of Hospitals Nationwide contributed to almost 75% of the tests while the balance was from non-KPJ hospitals and the Ministry of Health.

PHARMASERV ALLIANCES SDN BHD (PASB) is KPJ’s centralized wholesaler and distributor of pharmaceutical, medical disposables and other hospital related products. Its clients are the KPJ network of hospitals and companies, as well as external clients within the government sector and other healthcare sector players. PASB is able to achieve profitable growth and retain a competitive edge by transferring cost savings to customers. In 2019, its revenue increased to RM451.1 million.

Regardless of Covid 19 outbreak, KPJ remain resilient of its business model. The group switches over to ramp up testing services and can generate augur profit to offset any downturn during outbreak.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.

For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM1k-2k per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

There are 23 potential vaccines developed and 3 candidates already passed the clinical trial and go for final stage of testing.
1. Moderna vaccine enter the final stage of human trials for its COVID-19 vaccine on July 27.
2. Oxford-AstraZeneca Covid-19 vaccine show good immune responses without side effect.
3. Chinese-made vaccine from Sinovac Biotech at final stage of testing in Brazil.

PATHOLOGY SERVICES - LABLINK (M) SDN BHD provide laboratory/pathology services to the KPJ Group. It manages the pathology laboratories in KPJ’s network of hospitals. Lablink also conducts clinical tests for more than 100 non-KPJ institutions (including hospitals under the Ministry of Health and University Hospitals) as wellas general practitioners’ clinics across Malaysia. Lablink is the first lab in Malaysia to be certified with Bio-Safety Level 3 (BSL3) facilities which allows testing of highly infectious diseases (according to World Health Organization (WHO) standards). In Mar 2020, Lablink was one of the private laboratories listed by the Ministry of Health (MOH) to perform COVID-19 rRT-PCR (i.e. real-time reverse transcription polymerase chain reaction) by testing specimens received from hospitals: both from walk-in members of the public as well as hospital inpatients. Lablink recorded revenue of RM102.2 million in 2019.
The KPJ group of Hospitals classified Covid 19 rRT-PCR test according to urgent (result within 24 hours) and routine (beyond 24 hours). The COVID-19 testing capacity has been ramped up and Lablink has been able to test and report about 1,500-3,000 samples in a day in May 2020. The total number of samples, as at the end of May 2020 was in excess of 70,000; of which the KPJ-Group of Hospitals Nationwide contributed to almost 75% of the tests while the balance was from non-KPJ hospitals and the Ministry of Health.

PHARMASERV ALLIANCES SDN BHD (PASB) is KPJ’s centralized wholesaler and distributor of pharmaceutical, medical disposables and other hospital related products. Its clients are the KPJ network of hospitals and companies, as well as external clients within the government sector and other healthcare sector players. PASB is able to achieve profitable growth and retain a competitive edge by transferring cost savings to customers. In 2019, its revenue increased to RM451.1 million.

Regardless of Covid 19 outbreak, KPJ remain resilient of its business model. The group switches over to ramp up testing services and can generate augur profit to offset any downturn during outbreak.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.

For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM1k-2k per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

There are 23 potential vaccines developed and 3 candidates already passed the clinical trial and go for final stage of testing.
1. Moderna vaccine enter the final stage of human trials for its COVID-19 vaccine on July 27.
2. Oxford-AstraZeneca Covid-19 vaccine show good immune responses without side effect.
3. Chinese-made vaccine from Sinovac Biotech at final stage of testing in Brazil.

PATHOLOGY SERVICES - LABLINK (M) SDN BHD provide laboratory/pathology services to the KPJ Group. It manages the pathology laboratories in KPJ’s network of hospitals. Lablink also conducts clinical tests for more than 100 non-KPJ institutions (including hospitals under the Ministry of Health and University Hospitals) as wellas general practitioners’ clinics across Malaysia. Lablink is the first lab in Malaysia to be certified with Bio-Safety Level 3 (BSL3) facilities which allows testing of highly infectious diseases (according to World Health Organization (WHO) standards). In Mar 2020, Lablink was one of the private laboratories listed by the Ministry of Health (MOH) to perform COVID-19 rRT-PCR (i.e. real-time reverse transcription polymerase chain reaction) by testing specimens received from hospitals: both from walk-in members of the public as well as hospital inpatients. Lablink recorded revenue of RM102.2 million in 2019.
The KPJ group of Hospitals classified Covid 19 rRT-PCR test according to urgent (result within 24 hours) and routine (beyond 24 hours). The COVID-19 testing capacity has been ramped up and Lablink has been able to test and report about 1,500-3,000 samples in a day in May 2020. The total number of samples, as at the end of May 2020 was in excess of 70,000; of which the KPJ-Group of Hospitals Nationwide contributed to almost 75% of the tests while the balance was from non-KPJ hospitals and the Ministry of Health.

PHARMASERV ALLIANCES SDN BHD (PASB) is KPJ’s centralized wholesaler and distributor of pharmaceutical, medical disposables and other hospital related products. Its clients are the KPJ network of hospitals and companies, as well as external clients within the government sector and other healthcare sector players. PASB is able to achieve profitable growth and retain a competitive edge by transferring cost savings to customers. In 2019, its revenue increased to RM451.1 million.

Regardless of Covid 19 outbreak, KPJ remain resilient of its business model. The group switches over to ramp up testing services and can generate augur profit to offset any downturn during outbreak.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) thus the actual price for KPJ should be RM2.71.

Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.

For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM1k-2k per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

There are 23 potential vaccines developed and 3 candidates already passed the clinical trial and go for final stage of testing.
1. Moderna vaccine enter the final stage of human trials for its COVID-19 vaccine on July 27.
2. Oxford-AstraZeneca Covid-19 vaccine show good immune responses without side effect.
3. Chinese-made vaccine from Sinovac Biotech at final stage of testing in Brazil.

PATHOLOGY SERVICES - LABLINK (M) SDN BHD provide laboratory/pathology services to the KPJ Group. It manages the pathology laboratories in KPJ’s network of hospitals. Lablink also conducts clinical tests for more than 100 non-KPJ institutions (including hospitals under the Ministry of Health and University Hospitals) as wellas general practitioners’ clinics across Malaysia. Lablink is the first lab in Malaysia to be certified with Bio-Safety Level 3 (BSL3) facilities which allows testing of highly infectious diseases (according to World Health Organization (WHO) standards). In Mar 2020, Lablink was one of the private laboratories listed by the Ministry of Health (MOH) to perform COVID-19 rRT-PCR (i.e. real-time reverse transcription polymerase chain reaction) by testing specimens received from hospitals: both from walk-in members of the public as well as hospital inpatients. Lablink recorded revenue of RM102.2 million in 2019.
The KPJ group of Hospitals classified Covid 19 rRT-PCR test according to urgent (result within 24 hours) and routine (beyond 24 hours). The COVID-19 testing capacity has been ramped up and Lablink has been able to test and report about 1,500-3,000 samples in a day in May 2020. The total number of samples, as at the end of May 2020 was in excess of 70,000; of which the KPJ-Group of Hospitals Nationwide contributed to almost 75% of the tests while the balance was from non-KPJ hospitals and the Ministry of Health.

PHARMASERV ALLIANCES SDN BHD (PASB) is KPJ’s centralized wholesaler and distributor of pharmaceutical, medical disposables and other hospital related products. Its clients are the KPJ network of hospitals and companies, as well as external clients within the government sector and other healthcare sector players. PASB is able to achieve profitable growth and retain a competitive edge by transferring cost savings to customers. In 2019, its revenue increased to RM451.1 million.

Regardless of Covid 19 outbreak, KPJ remain resilient of its business model. The group switches over to ramp up testing services and can generate augur profit to offset any downturn during outbreak.

PHARMASERV ALLIANCES SDN BHD (PASB) is KPJ’s centralized wholesaler and distributor of pharmaceutical, medical disposables and other hospital related products. Its clients are the KPJ network of hospitals and companies, as well as external clients within the government sector and other healthcare sector players. PASB is able to achieve profitable growth and retain a competitive edge by transferring cost savings to customers. In 2019, its revenue increased to RM451.1 million.

Regardless of Covid 19 outbreak, KPJ remain resilient of its business model. The group switches over to ramp up testing services and can generate augur profit to offset any downturn during outbreak.

The KPJ group of Hospitals classified Covid 19 rRT-PCR test according to urgent (result within 24 hours) and routine (beyond 24 hours). The COVID-19 testing capacity has been ramped up and Lablink has been able to test and report about 1,500-3,000 samples in a day in May 2020. The total number of samples, as at the end of May 2020 was in excess of 70,000; of which the KPJ-Group of Hospitals Nationwide contributed to almost 75% of the tests while the balance was from non-KPJ hospitals and the Ministry of Health.

PATHOLOGY SERVICES - LABLINK (M) SDN BHD provide laboratory/pathology services to the KPJ Group. It manages the pathology laboratories in KPJ’s network of hospitals. Lablink also conducts clinical tests for more than 100 non-KPJ institutions (including hospitals under the Ministry of Health and University Hospitals) as wellas general practitioners’ clinics across Malaysia. Lablink is the first lab in Malaysia to be certified with Bio-Safety Level 3 (BSL3) facilities which allows testing of highly infectious diseases (according to World Health Organization (WHO) standards). In Mar 2020, Lablink was one of the private laboratories listed by the Ministry of Health (MOH) to perform COVID-19 rRT-PCR (i.e. real-time reverse transcription polymerase chain reaction) by testing specimens received from hospitals: both from walk-in members of the public as well as hospital inpatients. Lablink recorded revenue of RM102.2 million in 2019.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) however KPJ PE=17.47@RM0.83 thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.
For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM1k-2k per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

There are 23 potential vaccines developed and 3 candidates already passed the clinical trial and go for final stage of testing.
1. Moderna vaccine enter the final stage of human trials for its COVID-19 vaccine on July 27.
2. Oxford-AstraZeneca Covid-19 vaccine show good immune responses without side effect.
3. Chinese-made vaccine from Sinovac Biotech at final stage of testing in Brazil.

changing tide now

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) however KPJ PE=17.47@RM0.83 thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.
For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM1k-2k per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

There are 23 potential vaccines developed and 3 candidates already passed the clinical trial and go for final stage of testing.
1. Moderna vaccine enter the final stage of human trials for its COVID-19 vaccine on July 27.
2. Oxford-AstraZeneca Covid-19 vaccine show good immune responses without side effect.
3. Chinese-made vaccine from Sinovac Biotech at final stage of testing in Brazil.

There are 23 potential vaccines developed and 3 candidates already passed the clinical trial and go for final stage of testing.
1. Moderna vaccine enter the final stage of human trials for its COVID-19 vaccine on July 27.
2. Oxford-AstraZeneca Covid-19 vaccine show good immune responses without side effect.
3. Chinese-made vaccine from Sinovac Biotech at final stage of testing in Brazil.

There are 23 potential vaccines developed and 3 candidates already passed the clinical trial and go for final stage of testing.
1. Moderna vaccine enter the final stage of human trials for its COVID-19 vaccine on July 27.
2. Oxford-AstraZeneca Covid-19 vaccine show good immune responses without side effect.
3. Chinese-made vaccine from Sinovac Biotech at final stage of testing in Brazil.

There are 23 potential vaccines developed and 3 candidates already passed the clinical trial and go for final stage of testing.
1. Moderna vaccine enter the final stage of human trials for its COVID-19 vaccine on July 27.
2. Oxford-AstraZeneca Covid-19 vaccine show good immune responses without side effect.
3. Chinese-made vaccine from Sinovac Biotech at final stage of testing in Brazil.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) however KPJ PE=17.47@RM0.83 thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.
For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM1k-2k per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) however KPJ PE=17.47@RM0.83 thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.
For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM1k-2k per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) however KPJ PE=17.47@RM0.83 thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.
For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM1k-2k per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) however KPJ PE=17.47@RM0.83 thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.
For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM1k-2k per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) however KPJ PE=17.47@RM0.83 thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.
For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM1k-2k per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) however KPJ PE=17.47@RM0.83 thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.
For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM1k-2k per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) however KPJ PE=17.47@RM0.83 thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.
For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM1k-2k per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

Why KPJ is next gem for post covid-19?
Based on Fundamental analysis our current PE guideline is approx 57.14 (Based on 1.75% of BNM base rate) however KPJ PE=17.47@RM0.83 thus the actual price for KPJ should be RM2.71.
Covid-19 only good for medical sector (more clearly is protective medical equipment “glove, mask, face shield and etc” and diagnosis instrument “thermo scanners, PCR tester and etc” For Malaysia top glove, harta, kossan and supermx all are the first round winners.
For the last stage of vaccination development, now is the time to look for the next gem but unfortunately our country is impossible to produce these vaccine. The only vaccine we can get is import and we hv 20+mil ppl need to be vaccinated. Early stage of vaccine must be very expensive and gov won’t sponsor. We only can get vaccinated through private hospital no matter for travel or job requirement or just stay safe. Based on 2019, KPJ recorded 2,629,878 outpatients @ net profit 226.7mil with 28 hospitals overall the state. If half of 20mil ppl go KPJ for vaccination so approx net profit can reach up to 1bil. And u need to know tat those vaccine isn’t 1 injection for lifetime (like seasonally flu vaccine) and must get it semi or annually. RM1k-2k per vaccine per yrs for everyone to stay safe is new normal of post covid-19. And it is long term investment value of KPJ.

ISKANDAR WATERFELL..
how low to go

This is the reason

Brazil oil giant Petrobras posts record quarterly loss

Brazil's Petrobras, which is at the centre of a massive corruption scandal, has posted its biggest ever quarterly loss due to the plunge in oil prices.

The state oil firm's net loss widened to 36.9bn reais ($10.2bn; £7.1bn) in the three months to December.

The company had to write down billions of dollars from assets like oil fields and drilling rigs after crude prices fell by more than 40%.

Petrobras shares fell by nearly 6% in after hours US trading on the results.

Its chief executive said in a press conference that 2015 was "an extremely difficult year for the oil industry".
Weak demand

Petrobras has also been trying to deal with the fallout from an expanding corruption scandal that has gone to the top ranks of government and seen some of its former executives jailed.

On Monday police arrested a man in Portugal they say was laundering payments for two of the jailed Petrobras executives.

Police say the man, Raul Schmidt Felipe Junior, may also have acted as an intermediary between some foreign companies and Petrobras.

Brazil is also mired in its worst recession in a century, which has led to weak demand at home for its fuel products.

To maintain its finances, the firm has drastically reduced its spending and investment plans. Petrobras is also looking to sell some of its assets in order to raise more than $14bn.

so cheap $105mil for 40m oil plus 1 fpso in uk... how possible how much if oil go $100...

i buy some again...short term oil price still under depress plus petron already launch euro 4m gd for long run

pantech is integrated o&g com like dialog..oil price up or down no problem

falling naga no sleeping nage

the only loser of oil plunge is US as they produce the oil using usd and sell the oil also receive usd that why every month rig count drop. Russia is the most beneficial country due to usd strength ruble weaken and they feel no pain as using ruble to produce oil and earn usd when sell the oil.

gd news kzt gov juz lifted peg of tenge against usd. tenge was down 50% against usd since oil price plunge and u hv to know that suma hire kazakh work on oil field by paying tenge and export the oil which receive usd in return then will convert to rm as profit that also down 20 since oil price plunge. tat why suma still making profit with higher margin just play with those financial instrument.